Member Info for marik

Stick with the UT 132 masterclass, you are not made for commenting on this ...
Oh hang on, you don't know how that works either.

The UT 132 Masterclass by the T Team

The last time we received a masterclass by the T team on the closing price was on the 6th of October with the title "Like him or loathe him he's right". After a long lengthy effort to de-ramp Avacta, we saw an 8.25% share price rise from midday (Whatever you guys were doing, please don't stop). Today we are back on the subject of closing price, and we've so far been given a masterclass by the T team. I've taken some notes for summary:

- ignore the London Stock Exchange website for the closing price
- the opening price for the PI's tomorrow is dictated to by the ask price tonight
- the "official bid" of 116p at close will remain on the books at 8am when the market opens for PI's
- If you can't explain it, it's the Bill Gates and Warren Buffet effect

I've already finished my popcorn as the T team are MIA, but I am preparing a second batch ready for another masterclass later today or tomorrow (or whenever the T team are ready).

Disclaimer: these views are from the T team and not my own and should not be taken as advice, please DYOR.

Tony it's not a dream, Jogmec is in the frame - stockpiling for the stable securement of indispensable rare metals. The russians as per usual deliberately underestimate the resources, but double your estimates, it has 17.5b written all over it. I'm expecting news tonight.

£7.50 is my lower estimate. Enjoy.

Thanks Captain. Very interesting times on the horizon.

Long9 learn to read, I said not the T team.

Hi Ian,

Could you put me down for today. I'm expecting £7.50 per share and I've been getting the impression that we are getting very close.

Good luck all (not the T team) ;0)

Excellent post Sarah, thanks for sharing.

Very positive news! The pressure continues to grow for upwards momentum. Unfortunate for the numpties who are day are trading this and then spamming bulletin boards and twitter with negative comments to influence the share price. They wouldn't be progressing if there was a contraindication.

Avacta has made substantial progress over the last year but I 100% believe that the therapeutics arm will rerate the share price astronomically. Looking forward to the results before end of year.

"...assuming it’s positive, of course!), it would be a cash offer for the Therapeutics division only."

The diagnostics division would be in the mix for good reason as it has received in my opinion a dramatic boost to the infrastructure and publicity beyond what would conventionally be imagined pre-pandemic. With this in mind what was a smaller segment of the healthcare sector, is in the process of transforming itself to become a major player. So far the market has been flooded with inferior products from overseas, with little to no IP. But once the latest generation of LFTs (e.g. Affidx) hit the market in a bigger way, the mood amongst the major investors will change. With that in mind, I believe that larger investors are about to underline this area with a few substantial acquisitions over the next 6-12 months. I am not averse to a cheeky offer, but I would doubt that it would be less than £6Bn and think it will be for both therapeutics and diagnostics.

Yesterday the fourth cycle will have been administered. Which is another milestone for Avacta, the pressure will keep building to the upside.

@Ophidian, thanks. I was thinking more than £2.50, but let's see.

I agree the quicker to bring extra revenue speeds online, the faster the at capturing a decent slice. However, I would add that it is emerging quite quickly that the slice is pretty big - especially with the US news.

With the chemotherapy market estimated to be valued at more than $56Bn (11.5% CAGR) by 2024, there is a substantial market for AVA6000 to complement. Furthermore, the positive data from AVA6000 will add substantially to the chemotherapy market and pK data by the end of Q42021/ Q12022 will determine the pipeline and rerate the Avacta share price substantially.

This was released a while back, but now that the trial is underway, it's interesting to go back on what was stated.

Professor Chris Twelves, AVA6000 Study Chief Investigator, Leeds Teaching Hospitals Trust and the University of Leeds, commented:

“This is tremendous news. When I see patients with cancer I want to offer them more effective treatments with fewer side effects. My team are excited to be part of the AVA6000 Phase I first into human study and we look forward to enrolling patients into the clinical trial .”

More about Professor Chris Twelves here:
https://medicinehealth.leeds.ac.uk/medicine/staff/835/professor-chris-twelves

Alastair Smith (CEO) also stated that, This would open up a pipeline of next generation chemotherapies for the Group with significant clinical and commercial value in a chemotherapy market that is expected to grow to $56 billion by 2024.

https://avacta.com/phase-i-clinical-trial-authorisation-for-ava6000-approved-by-mhra/

@Infinis, yes there is a big shortage of global tests, which bodes well for the lft covid market.

Interesting thoughts Olly.

Great find @gadgie.

Great find poirot.

Have a good w.e. all.